Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pregnenolone 16α-carbonitrile is a synthetic steroidal compound that acts as a prototypical and effective agonist of the rodent pregnane X receptor (PXR). It is orally active and primarily used in research to study the effects of PXR activation. PXR is a ligand-dependent nuclear receptor involved in xenobiotic metabolism, regulating drug-metabolizing enzymes and drug transporters. Pregnenolone 16α-carbonitrile also functions as a glucocorticoid receptor antagonist and has been shown to induce the expression of cytochrome P450 enzymes, particularly the CYP3A family. It is used to investigate the regulation of steroidogenesis, including testosterone biosynthesis in rodent Leydig cells, where its activation of PXR leads to down-regulation of key steroidogenic enzymes and reduced testosterone production.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pregnenolone 16α-carbonitrile.